Japan Tissue Engineering Co.,Ltd. [7774.T]
TOKYO, Apr 24 (Pulse News Wire) – Japan Tissue Engineering CO.,LTD. (7774.T) reported a special loss of investment securities valuation impairment amounting to ¥149 million.
The company also revised its fiscal year 2026 earnings forecast due to recent performance trends and the aforementioned valuation impairment. In the latest update, the firm disclosed that the impairment charge would impact its net profit negatively. As a result, the projected net income per share was adjusted downward from -¥1330 to -¥1809, marking a decrease of -¥479 per share.
Sales revenue is expected to fall below previous forecasts primarily due to delays in lab site sales recognition, although the company’s autologous cultured cartilage product for knee osteoarthritis saw record monthly orders of 30 units in January 2026. Operational and ordinary profits are anticipated to remain stable thanks to cost-cutting measures. However, the overall outlook remains cautious, reflecting the significant impact of the investment losses.
The company emphasized that the revised figures are based on currently available data and could still undergo adjustments during ongoing audit processes.
Forecast revision — Downward revision
| Metric | Prior | Revised | Change |
|---|---|---|---|
| Revenue | ¥2,210M | ¥2,182M | -1.2% |
| Op. profit | ¥-550M | ¥-549M | |
| Net profit | ¥-540M | ¥-734M |
Source: TDNet filing · Figures in millions of yen
🟢 Confidence: High AI-translated content.